CORRIGAN MARK Insider Trading
Get the latest insider transactions of CORRIGAN MARK. CORRIGAN MARK is Executive VP, R&D in Sunovion Pharmaceuticals Inc. ($SEPR) and Executive, VP R&D in Sunovion Pharmaceuticals Inc. ($SEPR) and Director in NOVELION THERAPEUTICS INC. ($QLTI) and Director in EPIRUS Biopharmaceuticals, Inc. ($CRXX) and Director in CoLucid Pharmaceuticals, Inc. ($CLCD) and Director in Wave Life Sciences Ltd. ($WVE) and Director in Nabriva Therapeutics plc ($NBRV) and Director in Nabriva Therapeutics Plc ($NBRV). Discover the current value of CORRIGAN MARK shares.
Address: 84 WATERFORD DRIVE MARLBOROUGH 01752MA
CORRIGAN MARK is Insider in these Companies
Ticker | Company Name | Current and Previous Positions | Total Shares | Current Value ($) |
---|---|---|---|---|
SEPR | Sunovion Pharmaceuticals Inc. | Executive, VP R&D, Executive VP, R&D | 0 | 0.00 |
CRXX | EPIRUS Biopharmaceuticals, Inc. | Director | 0 | 0.00 |
CLCD | CoLucid Pharmaceuticals, Inc. | Director | 0 | 0.00 |
NVLN | NOVELION THERAPEUTICS INC. | Director | 0 | 0.00 |
NBRV | Nabriva Therapeutics Legacy plc | Director | 0 | |
NBRV | Nabriva Therapeutics plc | Director | 0 | 0.00 |
WVE | Wave Life Sciences Ltd. | Director | 0 | 0.00 |
Insider Trading Transactions of CORRIGAN MARK
Date | Ticker | Company | Owner | Relationship | Transaction | Cost ($) | Shares | Transaction Value ($) | Total Shares |
---|---|---|---|---|---|---|---|---|---|
Aug 20 2020 | WVE | Wave Life Sciences Ltd. | CORRIGAN MARK | Director | Option Exercise | 9.13 | 10,500 | 95,865 | 10,500 |
Sep 06 2019 | WVE | Wave Life Sciences Ltd. | CORRIGAN MARK | Director | Option Exercise | 21.03 | 21,000 | 441,630 | 21,000 |
Aug 01 2019 | NBRV | Nabriva Therapeutics plc | CORRIGAN MARK | Director | Option Exercise | 0.00 | 35,000 | 0 | 35,000 |
Aug 13 2018 | NVLN | NOVELION THERAPEUTICS INC ... | CORRIGAN MARK | Director | Option Exercise | 3.33 | 50,000 | 166,500 | 50,000 |
May 04 2018 | NBRV | Nabriva Therapeutics plc | CORRIGAN MARK | Director | Option Exercise | 0.00 | 29,000 | 0 | 29,000 |
Sep 19 2017 | NBRV | Nabriva Therapeutics plc | CORRIGAN MARK | Director | Option Exercise | 0.00 | 10,100 | 0 | 10,100 |
Jun 27 2017 | NBRV | Nabriva Therapeutics Plc | CORRIGAN MARK | Director | Option Exercise | 0.00 | 20,200 | 0 | 20,200 |
Jun 27 2017 | NBRV | Nabriva Therapeutics Plc | CORRIGAN MARK | Director | Option Exercise | 0.00 | 10,100 | 0 | 10,100 |
Mar 31 2017 | QLTI | NOVELION THERAPEUTICS INC ... | CORRIGAN MARK | Director | Option Exercise | 10.64 | 9,600 | 102,144 | 9,600 |
Mar 01 2017 | CLCD | CoLucid Pharmaceuticals, ... | CORRIGAN MARK | Director | Option Exercise | 3.79 | 8,114 | 30,752 | 0 |
Mar 01 2017 | CLCD | CoLucid Pharmaceuticals, ... | CORRIGAN MARK | Director | Option Exercise | 6.24 | 8,897 | 55,517 | 0 |
May 12 2016 | CLCD | CoLucid Pharmaceuticals, ... | CORRIGAN MARK | Director | Option Exercise | 6.24 | 8,897 | 55,517 | 8,897 |
Oct 29 2015 | CLCD | CoLucid Pharmaceuticals, ... | CORRIGAN MARK | Director | Option Exercise | 3.79 | 8,114 | 30,752 | 8,114 |
Jun 08 2015 | CRXX | EPIRUS Biopharmaceuticals ... | CORRIGAN MARK | Director | Option Exercise | 6.39 | 9,000 | 57,510 | 9,000 |
Oct 22 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 23.00 | 70,668 | 1,625,364 | 0 |
Oct 22 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Option Exercise | 16.78 | 70,000 | 1,174,600 | 0 |
Oct 22 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Option Exercise | 21.26 | 42,165 | 896,428 | 0 |
Oct 22 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Option Exercise | 14.40 | 57,500 | 828,000 | 0 |
Oct 19 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 23.00 | 20,749 | 477,227 | 70,668 |
May 14 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Buy | 14.40 | 35,000 | 504,000 | 91,417 |
May 14 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Option Exercise | 14.40 | 57,500 | 828,000 | 57,500 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.51 | 500 | 6,755 | 61,400 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.52 | 100 | 1,352 | 61,300 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.57 | 200 | 2,714 | 61,100 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.61 | 91 | 1,239 | 61,009 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.62 | 309 | 4,209 | 60,700 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.69 | 400 | 5,476 | 60,300 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.71 | 600 | 8,226 | 59,700 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.72 | 300 | 4,116 | 59,400 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.73 | 500 | 6,865 | 58,900 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.74 | 300 | 4,122 | 58,600 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.75 | 300 | 4,125 | 58,300 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.76 | 400 | 5,504 | 57,900 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.80 | 400 | 5,520 | 57,500 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.81 | 300 | 4,143 | 57,200 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.82 | 83 | 1,147 | 57,117 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.83 | 300 | 4,149 | 56,817 |
May 05 2009 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 13.86 | 400 | 5,544 | 56,417 |
Jun 05 2008 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 20.92 | 568 | 11,883 | 66,832 |
Jun 05 2008 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 20.93 | 1,832 | 38,344 | 65,000 |
Jun 05 2008 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Sell | 20.94 | 3,100 | 64,914 | 61,900 |
May 22 2008 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Buy | 21.26 | 35,000 | 744,100 | 67,400 |
May 22 2008 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Option Exercise | 21.26 | 42,165 | 896,428 | 42,165 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.97 | 5,150 | 241,896 | 147,068 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.98 | 2,000 | 93,960 | 145,068 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.99 | 2,234 | 104,976 | 142,834 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.00 | 3,884 | 182,548 | 138,950 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.01 | 3,300 | 155,133 | 135,650 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.02 | 5,400 | 253,908 | 130,250 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.03 | 1,650 | 77,600 | 128,600 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.04 | 1,500 | 70,560 | 127,100 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.05 | 1,100 | 51,755 | 126,000 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Buy | 47.06 | 2,288 | 107,673 | 123,712 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.07 | 7,081 | 333,303 | 116,631 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.08 | 7,321 | 344,673 | 109,310 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.09 | 6,248 | 294,218 | 103,062 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.10 | 4,671 | 220,004 | 98,391 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.11 | 4,691 | 220,993 | 93,700 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.12 | 2,100 | 98,952 | 91,600 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.13 | 2,200 | 103,686 | 89,400 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.14 | 2,532 | 119,358 | 86,868 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.15 | 4,400 | 207,460 | 82,468 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.16 | 3,468 | 163,551 | 79,000 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.17 | 2,200 | 103,774 | 76,800 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.18 | 2,200 | 103,796 | 74,600 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.19 | 3,726 | 175,830 | 70,874 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.20 | 3,136 | 148,019 | 67,738 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.21 | 3,661 | 172,836 | 64,077 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.22 | 2,203 | 104,026 | 61,874 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.23 | 2,854 | 134,794 | 59,020 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.24 | 2,220 | 104,873 | 56,800 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.25 | 7,385 | 348,941 | 49,415 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.26 | 5,005 | 236,536 | 44,410 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.27 | 2,500 | 118,175 | 41,910 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.28 | 1,000 | 47,280 | 40,910 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.29 | 600 | 28,374 | 40,310 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.30 | 320 | 15,136 | 39,990 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.31 | 400 | 18,924 | 39,590 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.32 | 280 | 13,250 | 39,310 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.33 | 800 | 37,864 | 38,510 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.34 | 500 | 23,670 | 38,010 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.35 | 300 | 14,205 | 37,710 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.36 | 30 | 1,421 | 37,680 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.37 | 600 | 28,422 | 37,080 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.38 | 200 | 9,476 | 36,880 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.39 | 900 | 42,651 | 35,980 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.40 | 3,000 | 142,200 | 32,980 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.41 | 200 | 9,482 | 32,780 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 47.42 | 380 | 18,020 | 32,400 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Buy | 16.78 | 140,000 | 2,349,200 | 172,400 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Buy | 27.70 | 40,000 | 1,108,000 | 212,400 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.67 | 300 | 14,001 | 212,100 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.68 | 100 | 4,668 | 212,000 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.69 | 1,600 | 74,704 | 210,400 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.70 | 600 | 28,020 | 209,800 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.71 | 800 | 37,368 | 209,000 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.72 | 500 | 23,360 | 208,500 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.73 | 300 | 14,019 | 208,200 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Buy | 46.75 | 2,100 | 98,175 | 206,100 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.76 | 473 | 22,117 | 205,627 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.77 | 2,318 | 108,413 | 203,309 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.78 | 1,740 | 81,397 | 201,569 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.79 | 1,209 | 56,569 | 200,360 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.80 | 2,560 | 119,808 | 197,800 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.81 | 2,540 | 118,897 | 195,260 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.82 | 3,500 | 163,870 | 191,760 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Buy | 46.83 | 4,103 | 192,143 | 187,657 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.84 | 1,900 | 88,996 | 185,757 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Buy | 46.85 | 1,800 | 84,330 | 183,957 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Buy | 46.86 | 3,477 | 162,932 | 108,480 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.87 | 2,182 | 102,270 | 178,298 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.88 | 1,600 | 75,008 | 176,698 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.89 | 1,425 | 66,818 | 175,273 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.90 | 5,058 | 237,220 | 170,215 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.91 | 3,397 | 159,353 | 166,818 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.92 | 4,300 | 201,756 | 162,518 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.93 | 2,200 | 103,246 | 160,318 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.94 | 1,500 | 70,410 | 158,818 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Sell | 46.96 | 6,600 | 309,936 | 152,218 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Option Exercise | 16.78 | 140,000 | 2,349,200 | 0 |
Jun 15 2007 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive, VP R&D | Option Exercise | 27.70 | 40,000 | 1,108,000 | 0 |
Feb 11 2004 | SEPR | Sunovion Pharmaceuticals ... | CORRIGAN MARK | Executive VP, R&D | Buy | 27.70 | 100,000 | 2,770,000 | 0 |